The short answer
Published tesamorelin dosing is one figure: 2mg once daily by subcutaneous injection, the dose used in both phase 3 programmes and carried onto the Egrifta label. The dosage charts and calculators found online restate that single number in different vial arithmetic. No published work establishes any other dose, and material here is supplied for laboratory research only.
Key facts
- Trial dose
- 2mg once daily, subcutaneous
- Where from
- Both phase 3 programmes
- Duration
- 26 weeks, with 52-week extension
- Label
- EGRIFTA carried the same 2mg figure
- Other doses
- None established in published work
- Research vials
- Supplied by mass (5mg); no dose applies
The one number in the record
Strip every tesamorelin dosage chart on the internet down to its source and one figure remains: 2mg once daily by subcutaneous injection. That is the dose both phase 3 programmes used, the dose the pooled analysis reports, and the dose the original EGRIFTA label carried. There is no published dose-ranging work establishing anything else in the approved indication.
Why dosage calculators exist
A peptide vial states mass; a syringe measures volume. A tesamorelin dosage calculator only bridges the two: dissolve a known mass in a known volume of bacteriostatic water and the concentration follows. Five milligrams into two millilitres is 2.5mg per millilitre, so each 0.1ml of solution carries 0.25mg. That is the entire mathematics. Anything a calculator adds beyond arithmetic is editorial.
Research material referenced
Tesamorelin 5mg, third-party HPLC tested
Per day, per week: what the trials scheduled
Daily, for the full trial. 26 weeks in the core phase 3 studies, out to 52 in the extension, with no loading phase, no cycling and no weekly schedule. Per-week totals quoted online are the daily figure multiplied by seven, not a separate regimen. Where a forum protocol departs from daily dosing, it has departed from the published record.
Dosage for fat loss: what that search actually finds
The association between tesamorelin and fat comes from its indication: excess visceral abdominal fat in HIV-associated lipodystrophy, where the 2mg trials measured roughly 15% visceral fat reduction by CT at 26 weeks. That is a population-specific, prescription-context result. No published trial establishes a tesamorelin dosage for fat loss in the general population, at 2mg or any other figure.
What a research vial is
Material here is a freeze-dried 5mg vial for laboratory research, not a course of anything. The trial numbers above are reported because they are the published record a researcher reads; they are not instructions, and the vial carries no dose because research use has none.
Quick reference
| Source | Form | Daily figure |
|---|---|---|
| Phase 3 trials (2007, 2010) | Subcutaneous injection | 2mg |
| EGRIFTA label (2010) | Patient injection kit | 2mg |
| Research vial (here) | Lyophilised 5mg powder | None; laboratory use only |
Frequently asked questions
- Is there an official tesamorelin dosage chart?
- The published record needs no chart: 2mg daily was the trial and label figure. Charts found online repackage that one number across vial strengths.
- What does a tesamorelin dosage calculator do?
- Concentration arithmetic only: mass dissolved over volume added. It cannot tell anyone what to take; it tells a researcher what each millilitre of a prepared solution contains.
- What was the tesamorelin dose in the fat trials?
- 2mg daily for 26 weeks, in HIV-associated lipodystrophy. No published fat-loss dosing exists outside that population.
- Why does the vial not state a dose?
- Because it is research material. Vials are specified by mass and purity; dosing belongs to medicines, and this is not one.
Continue researching
Peer-reviewed guides, comparators and matched reference materials.
Primary sources & clinical trials
Peer-reviewed research and registered trials from PubMed, ClinicalTrials.gov, PubChem, FDA and NIH. All links open in a new tab and point to the primary source, so every claim can be verified at origin.
- PubMedFalutz J et al., Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med 2007 (PMID 18057338)pubmed.ncbi.nlm.nih.gov
- PubMedFalutz J et al., Effects of tesamorelin (TH9507) in HIV-infected patients with excess abdominal fat: pooled phase 3 analysis. J Clin Endocrinol Metab 2010 (PMID 20554713)pubmed.ncbi.nlm.nih.gov
- FDADailyMed, EGRIFTA WR (tesamorelin) prescribing informationdailymed.nlm.nih.gov
- PubMedStanley TL et al., Tesamorelin, visceral fat and liver fat in HIV. JAMA 2014 (PMID 25038357)pubmed.ncbi.nlm.nih.gov
- PubChemPubChem · Tesamorelin (CID 16137828)pubchem.ncbi.nlm.nih.gov
- GuidelineGoogle: Creating helpful, reliable, people-first contentdevelopers.google.com
Written and reviewed by
William Heath · Editor, UK Peptides research library
William Heath edits the UK Peptides research library. He is responsible for what is published here: every article is sourced to primary literature, every purity or identity statement traces to a signed third-party certificate for a specific lot, and corrections are made in place with the review date updated. No scientific or medical credentials are claimed on this site; the evidence is carried by the cited sources and the certificates, not by the byline.
More Tesamorelin (GHRH Analogue) articles
- Tesamorelin Before and After: What the Trials MeasuredBefore-and-after tesamorelin results in the trials were CT scans, not photos: visceral fat fell roughly 15% over 26 weeks, then returned after stopping.
- What Is Tesamorelin? GHRH(1-44) With an FDA HistoryTesamorelin is the full 44-residue GHRH sequence with a hexenoyl group, and the one GHRH analogue holding an FDA approval. What it is, for researchers.